āshibio Exits Stealth Mode With $40 Million In Funding Led By Mpm Bio Impact, Appoints Pankaj Bhargava As CEO

Jun 20, 2024•about 1 year ago

Position

Chief Executive Officer

Company

āshibio

Pankaj Bhargava

CambridgeTherapeuticsBiotechnologyHealth Care

Description

Privately held biotechnology company āshibio exited stealth mode today with $40 million in seed and Series A financing led by MPM BioImpact. In addition, Dr. Pankaj Bhargava, founder of the company, has been appointed as Chief Executive Officer.

Company Information

Company

āshibio

Location

Cambridge, Massachusetts, United States

About

āshibio is a privately held biotechnology company focused on developing innovative therapeutics for bone and connective tissue disorders. The company is dedicated to advancing development of several investigative therapies, including a potential treatment for fibrodysplasia ossificans progressiva (FOP), a rare genetic disease characterized by severe and progressive heterotopic ossification.

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months

Related People

Pankaj hidden